CCM2

CCM2
Available structures
PDBOrtholog search: PDBe RCSB
Identifiers
Aliases CCM2, C7orf22, OSM, PP10187, CCM2 scaffolding protein
External IDs MGI: 2384924 HomoloGene: 12868 GeneCards: CCM2
Orthologs
Species Human Mouse
Entrez

83605

216527

Ensembl

ENSG00000136280

ENSMUSG00000000378

UniProt

Q9BSQ5

Q8K2Y9

RefSeq (mRNA)

NM_001029835
NM_001167934
NM_001167935
NM_031443

NM_001190343
NM_001190344
NM_146014

RefSeq (protein)

NP_001025006.1
NP_001161406.1
NP_001161407.1
NP_113631.1

NP_666126.1

Location (UCSC) Chr 7: 45 – 45.08 Mb Chr 11: 6.55 – 6.6 Mb
PubMed search [1] [2]
Wikidata
View/Edit HumanView/Edit Mouse

The CCM2 gene contains 10 coding exons and an alternatively spliced exon 1B. This gene is located on chromosome 7p13 and loss of function mutations on CCM2 lead to the onset of Cerebral Cavernous Malformations (CCM) illness.[3] Cerebral cavernous malformations (CCMs) are vascular malformations in the brain and spinal cord made of dilated capillary vessels.

Protein

Malcavernin is a protein that in humans is encoded by the CCM2 gene.[4][5] The normal function of malcavernin is to act as a scaffold for a variety of signaling complexes including p38 MAP Kinase.[6] This protein is also involved in regulating the cellular localization of the KRIT1 protein[7] and acts with the Rho Kinase signaling pathway to maintain normal blood vessel structure.[8][9]

Advocacy

For more information and support for Cerebral Cavernous Malformations Patients and their families, please visit the Angioma Alliance website: www.angioma.org

References

  1. "Human PubMed Reference:".
  2. "Mouse PubMed Reference:".
  3. Liquori, C. L.; Berg, M. J.; Siegel, A. M.; Huang, E.; Zawistowski, J. S.; Stoffer, T. P.; Verlaan, D.; Balogun, F.; Hughes, L.; Leedom, T. P.; Plummer, N. W.; Cannella, M.; Maglione, V.; Squitieri, F.; Johnson, E. W.; Rouleau, G. A.; Ptacek, L.; Marchuk, D. A. (2003). "Mutations in a Gene Encoding a Novel Protein Containing a Phosphotyrosine-Binding Domain Cause Type 2 Cerebral Cavernous Malformations". The American Journal of Human Genetics. 73 (6): 1459–1464. doi:10.1086/380314. PMC 1180409Freely accessible. PMID 14624391.
  4. Craig HD, Gunel M, Cepeda O, Johnson EW, Ptacek L, Steinberg GK, Ogilvy CS, Berg MJ, Crawford SC, Scott RM, Steichen-Gersdorf E, Sabroe R, Kennedy CT, Mettler G, Beis MJ, Fryer A, Awad IA, Lifton RP (Dec 1998). "Multilocus linkage identifies two new loci for a mendelian form of stroke, cerebral cavernous malformation, at 7p15-13 and 3q25.2-27". Hum Mol Genet. 7 (12): 1851–8. doi:10.1093/hmg/7.12.1851. PMID 9811928.
  5. "Entrez Gene: CCM2 cerebral cavernous malformation 2".
  6. Uhlik, M. T.; Abell, A. N.; Johnson, N. L.; Sun, W.; Cuevas, B. D.; Lobel-Rice, K. E.; Horne, E. A.; Dell'Acqua, M. L.; Johnson, G. L. (2003). "Rac–MEKK3–MKK3 scaffolding for p38 MAPK activation during hyperosmotic shock". Nature Cell Biology. 5 (12): 1104–1110. doi:10.1038/ncb1071. PMID 14634666.
  7. Zawistowski, J. S.; Stalheim, L.; Uhlik, M. T.; Abell, A. N.; Ancrile, B. B.; Johnson, G. L.; Marchuk, D. A. (2005). "CCM1 and CCM2 protein interactions in cell signaling: Implications for cerebral cavernous malformations pathogenesis". Human Molecular Genetics. 14 (17): 2521–2531. doi:10.1093/hmg/ddi256. PMID 16037064.
  8. Borikova, A. L.; Dibble, C. F.; Sciaky, N.; Welch, C. M.; Abell, A. N.; Bencharit, S.; Johnson, G. L. (2010). "Rho Kinase Inhibition Rescues the Endothelial Cell Cerebral Cavernous Malformation Phenotype". The Journal of Biological Chemistry. 285 (16): 11760–11764. doi:10.1074/jbc.C109.097220. PMC 2852911Freely accessible. PMID 20181950.
  9. Whitehead, K. J.; Chan, A. C.; Navankasattusas, S.; Koh, W.; London, N. R.; Ling, J.; Mayo, A. H.; Drakos, S. G.; Jones, D. A.; Zhu, G. E.; Marchuk, D. Y.; Davis, G. E.; Li, D. Y. (2009). "The Cerebral Cavernous Malformation signaling pathway promotes vascular integrity via Rho GTPases". Nature Medicine. 15 (2): 177–184. doi:10.1038/nm.1911. PMC 2767168Freely accessible. PMID 19151728.

Further reading


This article is issued from Wikipedia - version of the 6/6/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.